BioSyent Inc. (TSXV:RX)
Canada
· Delayed Price · Currency is CAD 14.50
-0.35 (-2.36%)
Apr 28, 2026, 3:46 PM EST
BioSyent Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 43.05 | 35.03 | 31.59 | 27.93 | 28.62 | Upgrade
|
| Revenue Growth (YoY) | 22.90% | 10.89% | 13.13% | -2.42% | 28.15% | Upgrade
|
| Cost of Revenue | 10.09 | 7.17 | 5.99 | 5.07 | 5.98 | Upgrade
|
| Gross Profit | 32.96 | 27.86 | 25.6 | 22.86 | 22.64 | Upgrade
|
| Selling, General & Admin | 21.77 | 18.67 | 18.13 | 15.88 | 14.45 | Upgrade
|
| Operating Expenses | 21.77 | 18.67 | 18.13 | 15.88 | 14.45 | Upgrade
|
| Operating Income | 11.19 | 9.18 | 7.47 | 6.98 | 8.18 | Upgrade
|
| Interest Expense | -0.05 | -0.06 | -0.07 | -0.08 | -0.09 | Upgrade
|
| Interest & Investment Income | 0.81 | 1.09 | 1.13 | 0.53 | 0.16 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.08 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 12.03 | 10.21 | 8.53 | 7.43 | 8.25 | Upgrade
|
| Asset Writedown | - | -0.43 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.13 | Upgrade
|
| Pretax Income | 12.03 | 9.78 | 8.53 | 7.43 | 8.38 | Upgrade
|
| Income Tax Expense | 3.02 | 2.51 | 2.07 | 1.97 | 2.1 | Upgrade
|
| Net Income | 9.01 | 7.27 | 6.46 | 5.46 | 6.28 | Upgrade
|
| Net Income to Common | 9.01 | 7.27 | 6.46 | 5.46 | 6.28 | Upgrade
|
| Net Income Growth | 23.96% | 12.54% | 18.35% | -13.11% | 65.51% | Upgrade
|
| Shares Outstanding (Basic) | 11 | 12 | 12 | 12 | 13 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 12 | 12 | 13 | 13 | Upgrade
|
| Shares Change (YoY) | -2.55% | -2.98% | -2.95% | -2.57% | -1.70% | Upgrade
|
| EPS (Basic) | 0.80 | 0.63 | 0.54 | 0.44 | 0.50 | Upgrade
|
| EPS (Diluted) | 0.78 | 0.62 | 0.53 | 0.43 | 0.49 | Upgrade
|
| EPS Growth | 27.11% | 16.01% | 22.07% | -10.86% | 68.28% | Upgrade
|
| Free Cash Flow | 8.97 | 8.63 | 5 | 4.9 | 4.59 | Upgrade
|
| Free Cash Flow Per Share | 0.78 | 0.73 | 0.41 | 0.39 | 0.36 | Upgrade
|
| Dividend Per Share | 0.200 | 0.180 | 0.160 | 0.040 | - | Upgrade
|
| Dividend Growth | 11.11% | 12.50% | 300.00% | - | - | Upgrade
|
| Gross Margin | 76.57% | 79.52% | 81.03% | 81.85% | 79.10% | Upgrade
|
| Operating Margin | 26.00% | 26.21% | 23.65% | 25.00% | 28.59% | Upgrade
|
| Profit Margin | 20.93% | 20.75% | 20.45% | 19.55% | 21.95% | Upgrade
|
| Free Cash Flow Margin | 20.83% | 24.64% | 15.81% | 17.55% | 16.04% | Upgrade
|
| EBITDA | 11.89 | 9.6 | 7.63 | 7.26 | 8.47 | Upgrade
|
| EBITDA Margin | 27.63% | 27.41% | 24.15% | 26.01% | 29.60% | Upgrade
|
| D&A For EBITDA | 0.7 | 0.42 | 0.16 | 0.28 | 0.29 | Upgrade
|
| EBIT | 11.19 | 9.18 | 7.47 | 6.98 | 8.18 | Upgrade
|
| EBIT Margin | 26.00% | 26.21% | 23.65% | 25.00% | 28.59% | Upgrade
|
| Effective Tax Rate | 25.09% | 25.68% | 24.30% | 26.54% | 25.03% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.